ACORN

Clarient, ACORN collaborate to improve cancer treatment

Wednesday, December 14, 2011

Clarient, a GE Healthcare company, and ACORN Research have formed a strategic collaboration around molecular testing of tumor samples. The agreement will establish a standardized testing protocol across the ACORN network of oncology community practices and hospitals with treatment guidelines and clinical trial opportunities. These processes have the potential to improve oncology treatment and research that aim to deliver targeted treatments based on the specific genetic markers for each patient.

[Read More]

ACORN reports positive research results

Friday, July 1, 2011

Accelerated Community Oncology Research Network (ACORN) reported positive results of a large, double-blind, randomized phase IIb trial in patients with breast cancer. The study evaluated a drug regimen for the treatment of locally advanced or metastatic breast cancer. The regimen, NexavarR (sorafenib) tablets in combination with either Gemcitabine (GemzarR) or Capecitabine (XelodaR), found statistically significant improvement in progression-free survival.  Forty investigative sites enrolled 160 patients over a three-year period.

[Read More]